Literature DB >> 25922081

Neurological picture. FDG-PET findings in three cases of Mills' syndrome.

Koen Van Laere1, Guido Wilms2, Philip Van Damme3.   

Abstract

Entities:  

Keywords:  ALS; MOTOR NEURON DISEASE; PET

Mesh:

Substances:

Year:  2015        PMID: 25922081      PMCID: PMC4752632          DOI: 10.1136/jnnp-2014-309952

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
Primary lateral sclerosis (PLS) is a rare subtype of motor neuron disease that exclusively affects upper motor neurons, usually beginning in the lower limbs and, less frequently in the bulbar region or the upper limbs.1 In contrast to amyotrophic lateral sclerosis (ALS), PLS typically has a symmetrical presentation and this characteristic was part of the initially proposed PLS criteria.2 We report 18-fluorodeoxyglucose-positron-emission tomography (FDG-PET) findings in three cases with an asymmetrical subtype of PLS, more commonly known as Mills’ syndrome.3 There is no universally accepted definition of Mills’ syndrome, but it is mostly referred to as a slowly progressive motor syndrome with unilateral or asymmetrical pyramidal signs.4 In this syndrome, the disease process remains more or less restricted to the motor areas contralateral to the affected side, as suggested by a study visualising microglial activation using 11C-(R)-PK11195 PET.5 Three female patients presented with an asymmetrical form of pure upper motor neuron dysfunction, starting in the right arm (patient 1 and 2) and the right leg (patient 3). The asymmetrical presentation correlated with clear regions of hypometabolism on FDG-PET in the contralateral Rolandic and peri-Rolandic areas, as can be seen in ALS or PLS6–8 (figure 1). MRI of the brain was unrevealing in all three patients. Extensive investigations did not reveal other underlying pathologies. Mutations in C9orf72, SOD1, FUS and TARDBP were excluded in all three patients. There was a concordance in limb dominance and site of onset, as all three patients were right handed.9
Figure 1

T2-weighted MRI (upper row) and stereotactic surface projections of the brain 18-fluorodeoxyglucose-positron-emission tomography (FDG-PET; middle row, cranial view) with corresponding Z-score images (comparing patient to healthy volunteers; lower row). No lesions on MRI that could explain the hypometabolism on FDG-PET were noted.

T2-weighted MRI (upper row) and stereotactic surface projections of the brain 18-fluorodeoxyglucose-positron-emission tomography (FDG-PET; middle row, cranial view) with corresponding Z-score images (comparing patient to healthy volunteers; lower row). No lesions on MRI that could explain the hypometabolism on FDG-PET were noted. No clinical or electrodiagnostic signs of lower motor neuron involvement were noted up to 8 (patient 1), 4 (patient 2) and 2 years (patient 3) after disease onset. Over this period of time, the disease spread from the right arm to the right leg and, to a lesser degree, to the contralateral side (patient 1), remained restricted to the right arm (patient 2) and spread from the right leg to the right arm (patient 3). This suggests a disease propagation by contiguous spread, as opposed to a network-spreading pattern through the corpus callosum in typical PLS.
  9 in total

1.  Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis.

Authors:  M R Turner; P Wicks; C A Brownstein; M P Massagli; M Toronjo; K Talbot; A Al-Chalabi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-06-18       Impact factor: 10.154

Review 2.  Primary lateral sclerosis.

Authors:  Mike A Singer; Jeffrey M Statland; Gil I Wolfe; Richard J Barohn
Journal:  Muscle Nerve       Date:  2007-03       Impact factor: 3.217

3.  Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study.

Authors:  Koen Van Laere; Annelies Vanhee; Jolien Verschueren; Liesbeth De Coster; An Driesen; Patrick Dupont; Wim Robberecht; Philip Van Damme
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

4.  Mills' syndrome: ascending (or descending) progressive hemiplegia: a hemiplegic form of primary lateral sclerosis?

Authors:  J L Gastaut; F Bartolomei
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-10       Impact factor: 10.154

5.  Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET.

Authors:  M R Turner; A Gerhard; A Al-Chalabi; C E Shaw; R A C Hughes; R B Banati; D J Brooks; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

6.  Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria.

Authors:  C E Pringle; A J Hudson; D G Munoz; J A Kiernan; W F Brown; G C Ebers
Journal:  Brain       Date:  1992-04       Impact factor: 13.501

7.  The stripe of primary lateral sclerosis: focal primary motor cortex hypometabolism seen on fluorodeoxyglucose F18 positron emission tomography.

Authors:  Daniel O Claassen; Keith A Josephs; Patrick J Peller
Journal:  Arch Neurol       Date:  2010-01

8.  Progressive hemiparesis in a 75-year-old man.

Authors:  Peter M Fernandes; Martin R Turner; Martin Zeidler; Colin Smith; Richard Davenport
Journal:  Pract Neurol       Date:  2014-09-24

9.  Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis.

Authors:  Marco Pagani; Adriano Chiò; Maria Consuelo Valentini; Johanna Öberg; Flavio Nobili; Andrea Calvo; Cristina Moglia; Davide Bertuzzo; Silvia Morbelli; Fabrizio De Carli; Piercarlo Fania; Angelina Cistaro
Journal:  Neurology       Date:  2014-08-13       Impact factor: 9.910

  9 in total
  2 in total

1.  Mills' syndrome is a unique entity of upper motor neuron disease with N-shaped progression: Three case reports.

Authors:  Zhi-Yun Zhang; Zhi-Yuan Ouyang; Guo-Hua Zhao; Jia-Jia Fang
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 2.  Mills' syndrome revisited.

Authors:  Stephan R Jaiser; Dipayan Mitra; Timothy L Williams; Mark R Baker
Journal:  J Neurol       Date:  2019-01-10       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.